Amvuttra was Alnylam Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $2.31B of $3.71B (62%).
| Product and Service | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Amvuttra | $93.80M | $557.84M | $970.45M | $2.31B | |
| Net Revenues From Collaborations | $134.91M | $546.19M | $510.22M | $553.37M | |
| Onpattro | $557.61M | $354.55M | $252.86M | $172.79M | |
| Givlaari | $173.14M | $219.25M | $255.87M | $308.49M | |
| Oxlumo | $69.78M | $109.84M | $167.05M | $191.44M | |
| Royalty Revenue | $8.18M | $40.63M | $91.79M | $174.02M | |
| Total | $1.04B | $1.83B | $2.25B | $3.71B |
Alnylam Pharmaceuticals brought in $3.71B from its six product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 65.2% from $2.25B in fiscal 2024. Amvuttra was the largest at $2.31B (62.3%), ahead of Net Revenues From Collaborations at $553.37M (14.9%) and Givlaari at $308.49M (8.3%). The other three lines brought in $538.25M combined.
Compared with fiscal 2024, Amvuttra grew fastest, up 138.4% to $2.31B, while Onpattro fell the most, down 31.7% to $172.79M. From fiscal 2022 to 2025, combined revenue from these lines grew from $1.04B to $3.71B, a compound annual growth rate of 53.0%. Amvuttra's share of the total rose from 9.0% to 62.3%.
Roche/Arrowhead was Alnylam Pharmaceuticals’s largest revenue line in fiscal 2012, bringing in $37.32M of $66.73M (56%).
| Collaborator | FY 2012 |
|---|---|
| Roche/Arrowhead | $37.32M |
| Takeda | $21.97M |
| Cubist | $2.78M |
| Other | $2.70M |
| Monsanto | $1.95M |
| Total | $66.73M |
Alnylam Pharmaceuticals brought in $66.73M from its five revenue lines in fiscal 2012, the year ended December 31, 2012. Roche/Arrowhead was the largest at $37.32M (55.9%), ahead of Takeda at $21.97M (32.9%) and Cubist at $2.78M (4.2%). The other two revenue lines brought in $4.66M combined.
Sanofi Genzyme was Alnylam Pharmaceuticals’s largest revenue line in fiscal 2017, bringing in $54.63M of $89.91M (61%).
| Counterparty Name | FY 2016 | FY 2017 |
|---|---|---|
| Sanofi Genzyme | $32.02M | $54.63M |
| Mdco | $11.22M | $30.22M |
| Other | $3.92M | $3.61M |
| Vir Biotechnology | — | $1.46M |
| Total | $47.16M | $89.91M |
Alnylam Pharmaceuticals brought in $89.91M from its four revenue lines in fiscal 2017, the year ended December 31, 2017. Alnylam Pharmaceuticals regrouped these revenue lines after fiscal 2016, so the total does not compare directly with that year's $47.16M. Sanofi Genzyme was the largest at $54.63M (60.8%), ahead of Mdco at $30.22M (33.6%) and Other at $3.61M (4.0%). The remaining revenue line, Vir Biotechnology, brought in $1.46M.
Compared with fiscal 2016, Mdco grew fastest, up 169.3% to $30.22M, while Other fell the most, down 8.1% to $3.61M.
Alnylam Pharmaceuticals began breaking out Vir Biotechnology in fiscal 2017, when it brought in $1.46M.
Alnylam Pharmaceuticals (ALNY) reports its revenue by product and service, by collaborator and by counterparty name. In fiscal 2025, Amvuttra was its largest product and service line, bringing in $2.31B (62.3% of the total), followed by Net Revenues From Collaborations at $553.37M (14.9%).
Amvuttra was Alnylam Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $2.31B, or 62.3% of the $3.71B total across its six product and service lines.
Roche/Arrowhead was Alnylam Pharmaceuticals' largest revenue line in fiscal 2012, bringing in $37.32M, or 55.9% of the $66.73M total across its five revenue lines.
Among Alnylam Pharmaceuticals' product and service lines that make up at least 2% of revenue, Amvuttra grew fastest in fiscal 2025, up 138.4% from $970.45M to $2.31B.
Every figure comes from Alnylam Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Alnylam Pharmaceuticals gives it, and years follow its fiscal calendar.
Alnylam Pharmaceuticals' revenue by product and service goes back to fiscal 2021, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.